UTHR
United Therapeutics Corporation
541.70$
-5.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 11.5% | 11.6% | 10.8% | 10.9% | 11.1% | 10.3% | 11.6% | 11.0% | 12.6% | 13.1% | 17.1% | 12.7% | 13.9% | |
| 88.5% | 88.4% | 89.2% | 89.1% | 88.9% | 89.7% | 88.4% | 89.0% | 87.4% | 86.9% | 82.9% | 87.3% | 86.1% | |
| 13.9% | 24.6% | 15.4% | 19.5% | 13.8% | 18.2% | 18.8% | 16.8% | 15.9% | 17.7% | 17.7% | 18.7% | 17.5% | |
| 17.5% | 17.6% | 17.9% | 21.3% | 26.5% | 18.4% | 18.1% | 20.0% | 19.2% | 19.9% | 19.9% | 17.6% | 19.1% | |
| 34.8% | 46.1% | 36.7% | 44.4% | 43.1% | 41.1% | 40.2% | 43.4% | 38.7% | 41.7% | 41.2% | 45.1% | 41.7% | |
| 53.7% | 42.3% | 52.6% | 44.7% | 45.8% | 48.6% | 48.2% | 45.6% | 48.7% | 45.2% | 41.7% | 42.2% | 44.5% | |
| 2.6% | 2.5% | 2.0% | 1.6% | 1.3% | 1.1% | 0.8% | 0.9% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | |
| 57.7% | 48.1% | 58.8% | 49.7% | 51.9% | 53.9% | 53.3% | 51.1% | 54.8% | 56.2% | 40.7% | 47.6% | 49.9% | |
| 13.8% | 12.7% | 13.6% | 10.8% | 10.6% | 12.9% | 12.8% | 12.4% | 12.4% | 10.1% | 5.6% | 5.1% | 8.3% | |
| 43.9% | 35.3% | 45.2% | 38.9% | 41.3% | 40.9% | 40.6% | 38.8% | 42.4% | 46.1% | 35.2% | 42.5% | 41.6% | |
| 62.5% | 52.7% | 63.0% | 53.9% | 55.8% | 57.6% | 55.0% | 54.7% | 57.9% | 59.5% | 44.0% | 48.0% | 52.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.